ALK and neuroblastoma: The other 12 candidate miRNAs were selected if they matched one or more of the following criteria: i) in silico prediction of potential ALK 3′-UTR targeting; ii) fold change in miRNAs expression > 2; iii) supporting data from literature for an involvement of the candidate miRNA with either ALK, NB or cancer in general.